On October 15th, Propanc Biopharma, a biopharmaceutical company that adopts the Ethereum treasury strategy, announced a strategic financing agreement of up to $100 million with the family office Hexstone Capital.
Propanc CEO James Nathanielsz said that the financing will accelerate the development of the company's clinical pipeline and plans to grow the value of the digital asset library to $100 million or more in the next 12 months. Hexstone Capital has previously invested in several companies with digital asset libraries, including BTC, ETH, SOL, DOGE and other digital assets.
Earlier in September, Propanc Biopharma announced plans to acquire $100 million Ethereum.
Ethereum treasury company Propanc Biopharma has reached a strategic financing agreement of up to $100 million with Hexstone Capital
2025-10-16 01:16:02
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
以太坊财库公司 Propanc Biopharma 与 Hexstone Capital 达成最高 1 亿美元战略融资协议Next article：
加密矿企 Core Scientific 董事会敦促股东投票支持 CoreWeave 的收购交易
